Tiago Fauth analyst WELLS FARGO

Currently out of the existing stock ratings of Tiago Fauth, 176 are a BUY (78.57%), 41 are a HOLD (18.3%), 7 are a SELL (3.13%).

Tiago Fauth

Work Performance Price Targets & Ratings Chart

Analyst Tiago Fauth, currently employed at WELLS FARGO, carries an average stock price target met ratio of 47.91% that have a potential upside of 23.88% achieved within 128 days.

Tiago Fauth’s has documented 443 price targets and ratings displayed on 44 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on LQDA, Liquidia Technologies.

Wall Street Analyst Tiago Fauth

Analyst best performing recommendations are on HGEN (HUMANIGEN).
The best stock recommendation documented was for HGEN (HUMANIGEN) at 7/13/2022. The price target of $0.5 was fulfilled within 2 days with a profit of $0.11 (18.03%) receiving and performance score of 90.16.

Average potential price target upside

ABCL Abcellera Biologics APLS Apellis Pharmaceuticals ASND Ascendis Pharma AS BCAB Bioatla IFRX InflaRx N.V. IMVT Immunovant KURA Kura Oncology ME 23Andme Holding Co UTHR United Therapeutics ALXO Alx Oncology Holdings ABSI Absci Corp AMGN Amgen ARGX argenx NV ADR ARNA Arena Pharmaceuticals BMRN Biomarin Pharmaceutical HGEN Humanigen ICPT Intercept Pharmaceuticals RARE Ultragenyx RXDX Prometheus Biosciences SPRB Spruce Biosciences EDIT Editas Medicine VTYX Ventyx Biosciences FMTX Forma Therapeutics Holdings GLTO Galecto ISEE IVERIC bio PYXS Pyxis Oncology VECT VectivBio Holding AG VRDN Viridian Therapeutics ALNY Alnylam Pharmaceuticals AVTE Aerovate Therapeutics INSM Insmed INZY Inozyme Pharma KROS Keros Therapeutics VRNA Verona Pharma PLC ADR WVE Wave Life Sciences Ltd TECX Tectonic Therapeutic LQDA Liquidia Technologies MNKD MannKind Corp PTCT PTC Therapeutics SVRA Savara BBIO BridgeBio Pharma PLRX Pliant Therapeutics HG Hamilton Insurance Group, Ltd. JAZZ Jazz Pharmaceuticals PLC

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 24-Sep-2026

$13

$-0.74 (-5.39%)

$24

10 days ago
(24-Sep-2026)

1/3 (33.33%)

$0.35 (2.77%)

4

Buy Since 05-Jan-2021

$9

$-4.74 (-34.50%)

$7

1 months 28 days ago
(06-Aug-2026)

4/8 (50%)

$2.47 (37.83%)

377

Buy Since 05-May-2026

$12

$-1.74 (-12.66%)

$7

1 months 28 days ago
(06-Aug-2026)

2/2 (100%)

$5.47 (83.77%)

33

Hold Since 05-Nov-2024

$11

$-2.74 (-19.94%)

2 months 27 days ago
(07-Jul-2026)

2/4 (50%)

$3.31 (43.04%)

561

Buy Since 10-Apr-2026

$11

$-2.74 (-19.94%)

$11

5 months ago
(04-May-2026)

2/2 (100%)

$6.41 (139.65%)

114

Show more analysts

Please expand the browser size to see the chart

Which stock is Tiago Fauth most bullish on?

Potential upside of $70.46 has been obtained for TECX (TECTONIC THERAPEUTIC)

Which stock is Tiago Fauth most reserved on?

Potential downside of $3.33 has been obtained for JAZZ (JAZZ PHARMACEUTICALS PLC)

What Year was the first public recommendation made by Tiago Fauth?

On 2017
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?